Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Glioblastoma × daratumumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 54 Recurrence 6 Neoplasms, Plasma Cell 5 Neoplasms 3 Smoldering Multiple Myeloma 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Paraproteinemias 1 Glioblastoma 1 Disease 1 Chromosome 17 deletion 1

Interventions

Temozolomide 38 Radiotherapy 16 Radiation 11 Nivolumab 9 Magnetic Resonance Spectroscopy 9 Specimen Handling 7 pembrolizumab 6 Bevacizumab 6 atezolizumab 4 Lomustine 4 olaparib 3 Photons 3 Ipilimumab 3 Immunoglobulin G 3 Disulfides 3 Diet, Ketogenic 3 Cyclophosphamide 3 trametinib 2 sargramostim 2 poly ICLC 2 pamiparib 2 niraparib 2 dabrafenib 2 azeliragon 2 Transurethral Resection of Bladder 2 Surveys and Questionnaires 2 Surgical Procedures, Operative 2 Standard of Care 2 Receptors, Interleukin-8B 2 Radiotherapy, Intensity-Modulated 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04922723 2025-04-18

PRIDE

West Virginia University

Phase 1/2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡